METiS Therapeutics is a biotechnology company that aims to drive therapies in a wide range of disease areas by integrating drug discovery and delivery with AI, machine learning, and quantum simulation.
Eko harnesses the power of smartphones and cloud data for monitoring patients with cardiovascular diseases. It has built a platform of non-invasive cardiovascular monitoring devices, clinical software, and point-of-care decision support algorithms to improve the delivery of cardiovascular care. In 2015, Eko launched the Eko Core Digital Stethoscope, the first FDA-cleared digital stethoscope on the market to wirelessly stream heart and lung sound to HIPAA-compliant software. For the first time in history, patient sounds can be integrated with electronic health records (EHRs) for more seamless referrals, documentation, and monitoring. Eko was established in 2013 and is based in Berkeley, California.
Cydar Limited develops a fusion imaging software to the healthcare industry. It offers Cydar Medical, a fusion imaging software that delivers automated 3D overlays into the operating room for surgical guidance. The company was incorporated in 2012 and is based in Barrington, United Kingdom with additional office in Wilmington, Delaware.
Curve Health, Inc. is an innovative online platform focused on enhancing senior care through a combination of telemedicine, health information exchange, predictive analytics, and smart billing. Established in 2020 and headquartered in New York, the platform allows physicians to provide remote care to patients in skilled nursing facilities, at home, or during transportation. By integrating these technologies, Curve Health has significantly reduced patient transfers from skilled nursing facilities to emergency departments by over 50%. The platform aims to streamline healthcare delivery, optimize staff allocation, and minimize readmissions while improving care quality and ensuring a seamless patient experience. Additionally, it facilitates efficient communication between hospital systems and post-acute facilities, accelerating reimbursements and enabling effective tracking of patient diagnoses and outcomes.
Casana is a healthcare technology company focused on heart health monitoring. It has developed the Heart Seat, an innovative product that integrates a toilet seat with a cardiovascular monitoring system. This device allows patients to conveniently track essential heart health metrics such as heart rate, blood pressure, cardiac output, ECG, and blood oxygenation from the comfort of their homes. The Heart Seat operates on a cloud-connected platform, enabling seamless data capture and analysis. Founded in 2018 and based in Rochester, New York, Casana aims to enhance heart health monitoring by providing a user-friendly solution that minimizes the need for active patient engagement.
Big Health is a London-based company that develops and markets digital healthcare solutions focused on improving mental health and sleep disorders. Its flagship product, Sleepio, is a digital sleep improvement program that utilizes Cognitive Behavioral Therapy techniques to address individual sleep challenges. The platform offers fully-automated, personalized therapeutic sessions, allowing users to engage with their specific issues and track their progress. In addition to Sleepio, Big Health provides a broader digital healthcare portal that delivers customized behavioral programs aimed at various mental health concerns, all designed in consultation with medical professionals to ensure efficacy and relevance.
ReviR Therapeutics is a genomics-based platform that develops novel medicines targeting human RNAs.
Virtue Diagnostics (Suzhou) Co., Ltd. is an in vitro diagnostic company established in 2019 and headquartered in Suzhou, China, with a research and development office in Singapore. The company specializes in developing advanced diagnostic technologies aimed at infectious diseases, cancer, and chronic diseases. Its offerings include clinical mass spectrometry, multiplex immunohistochemistry for pathology-based cancer detection, and a molecular and immunoassay platform. Through these technologies, Virtue Diagnostics aims to enhance disease detection and management, contributing to improved healthcare outcomes.
METiS Therapeutics is a biotechnology company that aims to drive therapies in a wide range of disease areas by integrating drug discovery and delivery with AI, machine learning, and quantum simulation.
Generate Biomedicines, Inc. specializes in developing a generative biology platform aimed at inventing novel therapeutic proteins, including antibodies, peptides, enzymes, and other related compounds. Utilizing advanced machine learning techniques, the platform analyzes the genetic code that determines protein function, allowing for the creation of new protein sequences optimized for therapeutic applications. This innovative approach enables the company to generate proteins that interact specifically and effectively with targeted therapeutic needs, facilitating the development of new drugs across various protein modalities. Founded in 2018 and located in Cambridge, Massachusetts, Generate Biomedicines was previously known as Generate Biologics, Inc. until its name change in March 2020.
MedRhythms Inc. is a neuro-rehabilitation company that specializes in neurologic music therapy, utilizing sensors, music, and artificial intelligence to enhance therapeutic outcomes. Founded in 2015 and headquartered in Portland, Maine, the company focuses on patients affected by conditions such as traumatic brain injury, stroke, Parkinson’s disease, and Huntington’s disease. MedRhythms develops evidence-based interventions aimed at improving walking, speech, cognitive abilities, and overall functional outcomes through the intersection of music and neuroscience. By employing innovative technology and direct brain stimulation techniques, the company aims to provide effective rehabilitation solutions that leverage the therapeutic benefits of music for neurological recovery.
Apnimed, Inc. is a clinical-stage company based in Cambridge, Massachusetts, focused on developing innovative pharmacologic therapies for sleep apnea and related disorders. Founded in 2017, the company aims to address the significant morbidity and mortality associated with sleep apnea, which affects over 20 million Americans. Apnimed's approach targets the neurobiological mechanisms that lead to airway obstruction, offering a simple, orally dosed treatment option. This strategy contrasts with current therapies, which primarily rely on positive pressure devices like CPAP, as well as other less commonly used methods such as mandibular advancement devices and surgical interventions. Apnimed's therapeutics are designed to alleviate both the physiological and symptomatic effects of obstructive sleep apnea, providing a safe and effective solution that addresses the underlying biology of the condition.
Shukun (Beijing) Network Technology Co., Ltd. operates as an artificial intelligence based medical technology company. It offers CareSphere Advisor that includes CoronaryDoc, a coronary heart disease intelligent auxiliary diagnosis system; FFRDoc, an intelligent blood flow reserve fraction CT-FFR measurement system; CACScoreDoc for calculating calcification points; and AortaDoc, an aortic intelligent diagnosis system. The company was founded in 2017 and is based in Beijing, China with a branch in Shanghai.
Medbanks Network Technology Co. Ltd., founded in 2014 and headquartered in Beijing, China, provides data processing services tailored for the healthcare industry. The company specializes in developing a multi-center database that aggregates and analyzes data reflecting China's patient population. Additionally, Medbanks creates an oncology database that incorporates clinical and professional medical services based on information collected from hospitals. This focus on data management and analysis aims to enhance healthcare services and research in China.
Curai is a virtual care company that leverages artificial intelligence to provide chat-based primary care services at reduced costs. Founded in 2017 by Neal Khosla and Xavier Amatriain, the company is headquartered in Palo Alto and aims to make high-quality, affordable primary care accessible globally. Curai's platform combines the expertise of clinicians with advanced AI technologies, facilitating a learning healthcare system that enhances the efficiency and effectiveness of care delivery. By helping patients communicate relevant information to medical professionals, Curai enables more accurate diagnoses and fosters improved patient outcomes. The service is available to individuals directly or through partnerships with enterprises.
Prescryptive Health, Inc. is a digital health company based in Redmond, Washington, that operates a prescription benefits platform aimed at enhancing accessibility, affordability, and personalization in the medication market. Established in 2017, the company provides a range of services, including the analysis of existing plan designs, recommendations for new plans, and assistance with member enrollment. Its platform offers users, including employers, health plans, providers, pharmacies, and pharmaceutical companies, direct access to unbiased market pricing and essential information about prescribed treatments. This enables patients to understand their out-of-pocket expenses, insurance coverage, and available lower-cost alternatives at the point of care, thereby promoting informed decision-making in the prescription drug market.
Shanghai Polaris Biology Co., Ltd. is a medical technology company focused on developing a cell diagnostic technology platform for tumors. Established in 2016 and based in Shanghai, China, the company utilizes artificial intelligence-based cell analysis models to examine dynamic changes in tumors at the cellular level. This innovative approach aims to enhance clinical tumor diagnosis and treatment by providing precise and accurate diagnostic tools for both patients and healthcare professionals. Polaris Biology is dedicated to advancing the understanding of individual tumor characteristics, thereby supporting more effective clinical decision-making in cancer care.
Big Health is a London-based company that develops and markets digital healthcare solutions focused on improving mental health and sleep disorders. Its flagship product, Sleepio, is a digital sleep improvement program that utilizes Cognitive Behavioral Therapy techniques to address individual sleep challenges. The platform offers fully-automated, personalized therapeutic sessions, allowing users to engage with their specific issues and track their progress. In addition to Sleepio, Big Health provides a broader digital healthcare portal that delivers customized behavioral programs aimed at various mental health concerns, all designed in consultation with medical professionals to ensure efficacy and relevance.
Cyted focuses on providing digital diagnostic infrastructure to drive the earlier detection of disease. Our technologies use artificial intelligence and novel biomarkers to unlock clinical insight and improve patient outcomes. Cyted's mission is to revolutionise diagnostic methods to build a world where disease is prevented rather than treated.
Xinjunte has focused on the research and development of intelligent medical devices for bone surgery, and is committed to providing more efficient and safe medical devices.
CairnSurgical is developing innovative patient-specific tools to guide surgical interventions for patients with cancer.
IMTherapeutics is a biotechnology company focused on creating personalized immunotherapeutic drugs for autoimmune diseases, utilizing genetic insights linked to human leukocyte antigen (HLA) genes. Founded in 2015 and based in Aurora, Colorado, the company’s lead candidate is an oral medication designed to inhibit the autoimmune process in type 1 diabetes (T1D) by targeting specific immune cells. This approach aims to preserve the function of pancreatic beta cells and support normal insulin production in patients at risk or in the early stages of T1D. Additionally, IMTherapeutics is leveraging its HLA platform to expand its drug pipeline to include treatments for Celiac disease and potentially other autoimmune disorders. The company employs advanced screening techniques and rational drug design to develop targeted therapeutic candidates, enhancing early detection and management of autoimmune conditions.
Meissa Vaccines, Inc. is a pharmaceutical development company based in San Mateo, California, established in 2014. The company focuses on advancing vaccines for respiratory syncytial virus (RSV), rhinovirus, and human metapneumovirus, addressing significant unmet medical needs, particularly in pediatrics. By in-licensing and developing these vaccines, Meissa Vaccines aims to mitigate the impact of respiratory illnesses, which are leading causes of infectious disease globally. The successful implementation of their vaccine programs could greatly reduce the incidence of acute lower respiratory tract diseases, alleviate symptoms associated with colds and asthma exacerbations, and ultimately lessen the burden on families by minimizing school and work absenteeism. The company's initiatives not only prioritize child health but also have the potential to benefit various age groups within the community.
MedAnnex Limited is a biotechnology company based in Edinburgh, United Kingdom, focused on developing innovative treatments for patients with autoimmune diseases and cancers. Established in 2009, the company is known for its lead product, annexuzlimab, a monoclonal antibody designed to address various autoimmune conditions. MedAnnex aims to create first-in-class antibody therapies that significantly enhance the quality of life for individuals affected by these serious health issues. Through its research and development efforts, the company is committed to advancing therapeutic options in the biotechnology sector.
Medvance is a pioneer in the development of 3D printed medical implants, specifically using PEEK materials. The company specializes in creating medical 3D printing equipment and software tailored for advanced medical engineering. By providing innovative 3D printing solutions, Medvance aims to enhance medical outcomes for patients and healthcare professionals. Its strategic partnership with Evonik ensures a reliable supply of raw materials, further supporting Medvance's mission to deliver cutting-edge medical technologies. The company's initiatives are focused on improving healthcare in China and expanding its impact globally.
Hangzhou Yunhu Technology Group Co.,Ltd develops an Internet platform for primary medical services in China. It offers a series of platform-based testing products; and a SaaS based LIS\HIS platform, designed for local medication institutions. It also provides a third party cold chain logistic services to support the blood and drug delivery. The company was founded in 2017 and is based in Hangzhou, China.
Shukun (Beijing) Network Technology Co., Ltd. operates as an artificial intelligence based medical technology company. It offers CareSphere Advisor that includes CoronaryDoc, a coronary heart disease intelligent auxiliary diagnosis system; FFRDoc, an intelligent blood flow reserve fraction CT-FFR measurement system; CACScoreDoc for calculating calcification points; and AortaDoc, an aortic intelligent diagnosis system. The company was founded in 2017 and is based in Beijing, China with a branch in Shanghai.
Shanghai Polaris Biology Co., Ltd. is a medical technology company focused on developing a cell diagnostic technology platform for tumors. Established in 2016 and based in Shanghai, China, the company utilizes artificial intelligence-based cell analysis models to examine dynamic changes in tumors at the cellular level. This innovative approach aims to enhance clinical tumor diagnosis and treatment by providing precise and accurate diagnostic tools for both patients and healthcare professionals. Polaris Biology is dedicated to advancing the understanding of individual tumor characteristics, thereby supporting more effective clinical decision-making in cancer care.
GeneDock, founded in September 2014, is a national high-tech enterprise specializing in precision medical data technology. The company develops and provides a comprehensive SaaS platform that allows users to extract, analyze, and visualize medical records, facilitating improved research and studies for medical and scientific institutions. With industry-leading expertise, GeneDock has successfully built data platforms for numerous prominent facilities, including top three hospitals and leading industry organizations in China. The core team comprises members with backgrounds from renowned companies, and the firm has attracted investment from notable institutions. GeneDock aims to drive innovation in healthcare through advanced data technology solutions.
Shukun (Beijing) Network Technology Co., Ltd. operates as an artificial intelligence based medical technology company. It offers CareSphere Advisor that includes CoronaryDoc, a coronary heart disease intelligent auxiliary diagnosis system; FFRDoc, an intelligent blood flow reserve fraction CT-FFR measurement system; CACScoreDoc for calculating calcification points; and AortaDoc, an aortic intelligent diagnosis system. The company was founded in 2017 and is based in Beijing, China with a branch in Shanghai.
WeDoctor Holdings (Zhejiang) Co., Ltd. is a prominent medical technology platform based in Hangzhou, China, founded in 2010. The company specializes in developing medical cloud and artificial intelligence solutions that cater to governments, hospitals, and healthcare institutions. WeDoctor provides a comprehensive cloud platform that facilitates both online and offline medical services, including general practice, specialty consultations, and appointment scheduling. Additionally, it operates a managed health services platform known as WeDoctor HMO, aimed at enhancing medical care accessibility and efficiency. By leveraging technology, WeDoctor strives to improve health management for users, positioning itself as a significant player in the health maintenance organization sector. Through its innovative approach, the company aims to serve as a crucial health resource for millions of families.
Ishen365 develops and operates renal care service platform for healthcare sector. It provides chronic disease management solutions for patients with kidney disease. The company is based in Shanghai, China.
Etong Healthcare
Series B in 2017
EtongOnline Shanghai Medical Consulting provides third-party health management services to large and medium-sized enterprises in Shanghai, Beijing, Shenzhen, Guangzhou, Wuhan, & Chengdu. Its healthy management services include file recording, health assessment, health intervention, health education, health consultation, and private doctor services. The company also provides health examination services, such as employment health check, physical examination, PET-CT testing, gene detection, and enterprise welfare health check services. In addition, it offers medical services, such as medical guidance, specialist appointment, admission solutions, surgery appointment, secondary consultation, and particular examination arrangement services. Further, the company provides services in the areas of establishment of health infirmary, enterprise stratified health management, overseas medical, medical tourism, liability insurance, and oral care. EtongOnline Shanghai Medical Consulting was founded in 2009 and is headquartered in Shanghai City, China.
Hangzhou Yunhu Technology Group Co.,Ltd develops an Internet platform for primary medical services in China. It offers a series of platform-based testing products; and a SaaS based LIS\HIS platform, designed for local medication institutions. It also provides a third party cold chain logistic services to support the blood and drug delivery. The company was founded in 2017 and is based in Hangzhou, China.
Xiaolu Clinic is an online platform connecting traditional Chinese medicine providers with consumers. It offers online traditional Chinese medicine consultancy services for patients with chronic disease and those suffering from sub-optimal health, areas that traditional Chinese medicine might treat with herbal mixtures and dietary augmentation. Users can be evaluated by traditional Chinese medicine doctors and purchase herbal remedies online, as well as engage in treatment monitoring and post-treatment analysis. It also provides health management services for staff at big companies, including Baidu Inc., China Life Insurance (Group) Co., and Tencent Holdings Ltd. The Beijing-based company was founded in 2016.
Shenzhen Easyhin Technology Co., Ltd. specializes in maternal and child health through its online application, Mommy Knows. Founded in 2014 and based in Shenzhen, China, the company provides a range of clinical services, including pediatric checkups, ENT care, nutrition, and dentistry. Easyhin combines cross-border healthcare with Internet technology, aiming to create innovative health management solutions for mothers and children. The company leverages expertise from seasoned professionals in the healthcare and technology sectors to develop its services. It has gained recognition for its mobile health management platform, which aims to deliver comprehensive health services conveniently to users, addressing various personal healthcare needs.
Private Equity Round in 2015
WeDoctor Holdings (Zhejiang) Co., Ltd. is a prominent medical technology platform based in Hangzhou, China, founded in 2010. The company specializes in developing medical cloud and artificial intelligence solutions that cater to governments, hospitals, and healthcare institutions. WeDoctor provides a comprehensive cloud platform that facilitates both online and offline medical services, including general practice, specialty consultations, and appointment scheduling. Additionally, it operates a managed health services platform known as WeDoctor HMO, aimed at enhancing medical care accessibility and efficiency. By leveraging technology, WeDoctor strives to improve health management for users, positioning itself as a significant player in the health maintenance organization sector. Through its innovative approach, the company aims to serve as a crucial health resource for millions of families.
WeDoctor Holdings (Zhejiang) Co., Ltd. is a prominent medical technology platform based in Hangzhou, China, founded in 2010. The company specializes in developing medical cloud and artificial intelligence solutions that cater to governments, hospitals, and healthcare institutions. WeDoctor provides a comprehensive cloud platform that facilitates both online and offline medical services, including general practice, specialty consultations, and appointment scheduling. Additionally, it operates a managed health services platform known as WeDoctor HMO, aimed at enhancing medical care accessibility and efficiency. By leveraging technology, WeDoctor strives to improve health management for users, positioning itself as a significant player in the health maintenance organization sector. Through its innovative approach, the company aims to serve as a crucial health resource for millions of families.
Kona Medical, Inc. is a medical technology company based in Issaquah, Washington, founded in 2009 by Dr. Michael Gertner. The company specializes in developing a non-invasive ultrasound-based therapy system aimed at treating hypertension and related disorders. Its primary product, Surround Sound, is a hypertension therapy system that employs ultrasound imaging to precisely deliver focused ultrasound energy for renal denervation. This innovative approach targets the nerves associated with kidney function, offering a less invasive alternative for patients suffering from drug-resistant hypertension. By leveraging advancements in therapeutic focused ultrasound, Kona Medical seeks to improve treatment efficacy and reduce the health risks associated with high blood pressure.
Advanced Cell Diagnostics, Inc. specializes in developing and commercializing cell and tissue-based diagnostic tests aimed at advancing personalized medicine. The company employs its proprietary RNAscope technology, which enables the detection and quantification of RNA biomarkers at single-molecule sensitivity through multiplex fluorescent and chromogenic in situ hybridization. Its product offerings include manual assays, reagent kits, and catalog probes, as well as software for quantitative analysis of RNA samples and instruments for manual assay workflows. Advanced Cell Diagnostics also provides pharmaceutical assay services to facilitate understanding of disease mechanisms in preclinical research, target validation, and clinical trials. Additionally, the company has a companion diagnostic assay development program to optimize the assay development process. Its products are distributed through various channels, including international markets, and are also available for online purchase. Founded in 2007 and located in Hayward, California, the company operates as a subsidiary of Bio-Techne Corp.
Mirna Therapeutics, Inc. is a discovery-stage biopharmaceutical company that specializes in developing miRNA-directed therapies for human oncology. With a strong focus on research and a deep understanding of microRNA and cancer biology, Mirna is positioned to advance the emerging field of miRNA-based therapeutics. The company boasts a robust intellectual property portfolio that supports its innovative approach to cancer treatment.
Developer of a medical assistant application software based on artificial intelligence technology. The company's application software provides users with private doctor services, and has now opened consulting services for obstetrics and gynecology and pediatrics, enabling users to have medical services remotely.
WeDoctor Holdings (Zhejiang) Co., Ltd. is a prominent medical technology platform based in Hangzhou, China, founded in 2010. The company specializes in developing medical cloud and artificial intelligence solutions that cater to governments, hospitals, and healthcare institutions. WeDoctor provides a comprehensive cloud platform that facilitates both online and offline medical services, including general practice, specialty consultations, and appointment scheduling. Additionally, it operates a managed health services platform known as WeDoctor HMO, aimed at enhancing medical care accessibility and efficiency. By leveraging technology, WeDoctor strives to improve health management for users, positioning itself as a significant player in the health maintenance organization sector. Through its innovative approach, the company aims to serve as a crucial health resource for millions of families.
WeDoctor Holdings (Zhejiang) Co., Ltd. is a prominent medical technology platform based in Hangzhou, China, founded in 2010. The company specializes in developing medical cloud and artificial intelligence solutions that cater to governments, hospitals, and healthcare institutions. WeDoctor provides a comprehensive cloud platform that facilitates both online and offline medical services, including general practice, specialty consultations, and appointment scheduling. Additionally, it operates a managed health services platform known as WeDoctor HMO, aimed at enhancing medical care accessibility and efficiency. By leveraging technology, WeDoctor strives to improve health management for users, positioning itself as a significant player in the health maintenance organization sector. Through its innovative approach, the company aims to serve as a crucial health resource for millions of families.
Kona Medical, Inc. is a medical technology company based in Issaquah, Washington, founded in 2009 by Dr. Michael Gertner. The company specializes in developing a non-invasive ultrasound-based therapy system aimed at treating hypertension and related disorders. Its primary product, Surround Sound, is a hypertension therapy system that employs ultrasound imaging to precisely deliver focused ultrasound energy for renal denervation. This innovative approach targets the nerves associated with kidney function, offering a less invasive alternative for patients suffering from drug-resistant hypertension. By leveraging advancements in therapeutic focused ultrasound, Kona Medical seeks to improve treatment efficacy and reduce the health risks associated with high blood pressure.
MicuRx discovers and develops novel antibiotics to combat drug resistant bacterial infections. Founded in 2007, MicuRx employs a hybrid U.S./China business model to capitalize on the global opportunities afforded by U.S. research and development coupled with the high-quality, cost-efficient infrastructure and scientific resources available in China. This hybrid business model enables MicuRx to implement an accelerated global development strategy with a goal of completing Phase II trials for its drug candidates in both the United States and China.
Advanced Cell Diagnostics, Inc. specializes in developing and commercializing cell and tissue-based diagnostic tests aimed at advancing personalized medicine. The company employs its proprietary RNAscope technology, which enables the detection and quantification of RNA biomarkers at single-molecule sensitivity through multiplex fluorescent and chromogenic in situ hybridization. Its product offerings include manual assays, reagent kits, and catalog probes, as well as software for quantitative analysis of RNA samples and instruments for manual assay workflows. Advanced Cell Diagnostics also provides pharmaceutical assay services to facilitate understanding of disease mechanisms in preclinical research, target validation, and clinical trials. Additionally, the company has a companion diagnostic assay development program to optimize the assay development process. Its products are distributed through various channels, including international markets, and are also available for online purchase. Founded in 2007 and located in Hayward, California, the company operates as a subsidiary of Bio-Techne Corp.
WeDoctor Holdings (Zhejiang) Co., Ltd. is a prominent medical technology platform based in Hangzhou, China, founded in 2010. The company specializes in developing medical cloud and artificial intelligence solutions that cater to governments, hospitals, and healthcare institutions. WeDoctor provides a comprehensive cloud platform that facilitates both online and offline medical services, including general practice, specialty consultations, and appointment scheduling. Additionally, it operates a managed health services platform known as WeDoctor HMO, aimed at enhancing medical care accessibility and efficiency. By leveraging technology, WeDoctor strives to improve health management for users, positioning itself as a significant player in the health maintenance organization sector. Through its innovative approach, the company aims to serve as a crucial health resource for millions of families.
The Kang San Global Medical Technology (Beijing) Co., Ltd. is a hi-tech enterprise of one for the country at all levels of the hospital to provide advanced specialist inspection services, and the establishment of the National Laboratory of Kang Sheng Global Medical Special Inspection Center. Of the center's national service network belongs wholly owned ...
Kindstar Global (Beijing) Technology, Inc. is a Chinese provider of specialty clinical testing services, primarily serving hospitals across the country, including tertiary care facilities. Founded in 2003 and headquartered in Wuhan, the company specializes in esoteric diagnostic testing and laboratory services. It also offers medical research, clinical trial services, and translational medicine studies to healthcare professionals and pharmaceutical companies. Kindstar Global is committed to developing advanced medical testing technologies and adheres to international standards and guidelines. The company operates laboratory facilities in major cities such as Beijing, Shanghai, and Wuhan, and maintains strategic partnerships, including one with ImmunArray, to enhance its service offerings.
Chimerix, Inc. is a biopharmaceutical company based in Durham, North Carolina, dedicated to developing innovative antiviral therapeutics for patients with serious diseases, including cancer and those undergoing transplant procedures. The company’s lead candidate, CMX001, targets life-threatening double-stranded DNA viral infections and has demonstrated antiviral activity in clinical studies involving immunocompromised patients. Ongoing research includes a Phase 2 study for preventing cytomegalovirus in stem cell transplant recipients and other studies addressing adenovirus and various herpes viruses. Chimerix is also developing CMX157, a nucleoside analogue aimed at treating HIV and hepatitis B, which has shown promising results in early trials. Additionally, the company is working on dociparstat sodium, a compound intended to inhibit key proteins linked to acute myeloid leukemia, and brincidofovir, an antiviral candidate for smallpox. Chimerix holds various licensing agreements to advance its research and has received substantial federal funding to support its initiatives in public health and medical countermeasures.
ProterixBio, Inc. specializes in developing disease management platforms aimed at improving patient outcomes in chronic respiratory diseases, particularly chronic obstructive pulmonary disease, cystic fibrosis, and idiopathic pulmonary fibrosis. The company utilizes its proprietary ViBE platform and Acoustic Membrane MicroParticle (AMMP) assays to facilitate the precise analysis of proteins in various biological samples, including blood and sputum. The AMMP technology employs a non-optical, homogeneous assay approach, which enhances the sensitivity and specificity of traditional reagents through the integration of biological capture strategies and advanced acoustic sensors. By providing real-time biological assessments of a patient's disease state, ProterixBio's products support healthcare providers in managing chronic conditions more effectively, reducing the need for hospitalizations, and ultimately lowering healthcare costs. Founded in 2002 and based in Billerica, Massachusetts, ProterixBio was previously known as BioScale, Inc. before rebranding in May 2016.
Advanced Cell Diagnostics, Inc. specializes in developing and commercializing cell and tissue-based diagnostic tests aimed at advancing personalized medicine. The company employs its proprietary RNAscope technology, which enables the detection and quantification of RNA biomarkers at single-molecule sensitivity through multiplex fluorescent and chromogenic in situ hybridization. Its product offerings include manual assays, reagent kits, and catalog probes, as well as software for quantitative analysis of RNA samples and instruments for manual assay workflows. Advanced Cell Diagnostics also provides pharmaceutical assay services to facilitate understanding of disease mechanisms in preclinical research, target validation, and clinical trials. Additionally, the company has a companion diagnostic assay development program to optimize the assay development process. Its products are distributed through various channels, including international markets, and are also available for online purchase. Founded in 2007 and located in Hayward, California, the company operates as a subsidiary of Bio-Techne Corp.
MetaCure Limited is a medical device company focused on developing and commercializing minimally invasive solutions for metabolic and gastric conditions, particularly type 2 diabetes. Founded in 2003 and headquartered in Hamilton, Bermuda, with an additional office in Düsseldorf, Germany, the company has created innovative products such as the DIAMOND system and Tantalus. These devices deliver electrical stimulation to the stomach during meals, promoting gastric contractions to help regulate blood glucose levels and provide an alternative to insulin treatments. MetaCure aims to address the growing prevalence of type 2 diabetes and obesity through its advanced therapeutic solutions, primarily targeting markets in the United States, Europe, and Asia.
HD Biosciences Inc. is a Shanghai-based biotechnology company that specializes in contract research for drug discovery. The company has developed a comprehensive range of technology platforms and expertise in areas such as assay development, high throughput drug screening, structure-activity relationship (SAR) studies, and hit-to-lead biology solutions. Additionally, it focuses on natural product-based lead discovery. HD Biosciences has established long-term research agreements with notable clients, including Pfizer and Organon, positioning itself as a leader in biology-based drug discovery in China. Its services encompass a variety of stages in the drug discovery process, from assay development and validation to hit identification and in vivo pharmacology, catering to the needs of pharmaceutical and biotech companies globally.
Inimex Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Burnaby, Canada, specializing in the development and commercialization of Innate Defense Regulators (IDRs). These innovative drugs are designed to selectively modulate the body's innate immune defenses without inducing inflammation. The company's lead product, IMX942, aims to enhance survival rates, reduce tissue damage, and mitigate bacterial infections. Inimex's IDR products target a range of medical conditions, including infections and tissue injury-related ailments such as ventilator-associated pneumonia, tracheobronchitis, bacteremia, endocarditis, mucositis, and certain cancers. Founded in 2001, Inimex Pharmaceuticals is dedicated to advancing its unique therapies to improve patient outcomes.
The Kang San Global Medical Technology (Beijing) Co., Ltd. is a hi-tech enterprise of one for the country at all levels of the hospital to provide advanced specialist inspection services, and the establishment of the National Laboratory of Kang Sheng Global Medical Special Inspection Center. Of the center's national service network belongs wholly owned ...
MicuRx discovers and develops novel antibiotics to combat drug resistant bacterial infections. Founded in 2007, MicuRx employs a hybrid U.S./China business model to capitalize on the global opportunities afforded by U.S. research and development coupled with the high-quality, cost-efficient infrastructure and scientific resources available in China. This hybrid business model enables MicuRx to implement an accelerated global development strategy with a goal of completing Phase II trials for its drug candidates in both the United States and China.